Beyond Air to Participate in the 38th Annual Roth Conference in March GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 38th Annual Roth Conference being held March 22nd to 24th in Laguna Niguel, CA. 38th Annual Roth ConferenceFormat:Fireside chat and one-on-one meeti...
CVG Reports Fourth Quarter and Full Year 2025 Results Fourth quarter sales of $155 million, EPS of ($0.19), Adjusted EBITDA of $2.3 million CVG named Zoox Robotaxi low voltage wire harness strategic supplier Provides outlook and guidance for full year 2026 NEW ALBANY, Ohio, March 10, 2026 (GLOBE NEWSWIRE) -- CVG (NASDAQ: CVGI), a diversified industrial products and services company, today announced financial results for its fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights (Compared with prior-year period, where comparisons are noted) Revenue of $15...
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals Ltd. (“XTL”) relating to Beyond Air’s NeuroNOS subsidiary has been terminated. The companies entered into a letter of i...
Anika Reports Fourth Quarter and Full Year 2025 Financial Results Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain manag...
A director at American Assets Trust Inc bought 82,386 shares at 19.417USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
CVG Announces Fourth Quarter and Full Year 2025 Earnings Call NEW ALBANY, Ohio, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Commercial Vehicle Group (the “Company” or “CVG”) (NASDAQ: CVGI) will hold its quarterly conference call on Wednesday, March 11, 2026, at 8:30 a.m. ET, to discuss fourth quarter and full year 2025 financial results. CVG will issue a press release and presentation prior to the conference call. Toll-free participants dial (800) 549-8228 using conference code 51917. International participants dial (289) 819-1520 using conference code 51917. This call is being webcast and can be...
A director at Louisiana-Pacific Corp bought 20,000 shares at 85.490USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑d...
A director at Douglas Emmett Inc bought 98,000 shares at 10.180USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the under the Investors section of Anika Therapeuti...
U.S. Cyber Command Issues Parsons’ Subsidiary Intent to Award for Joint Cyber Hunt Kit (JCHK) Production SealingTech, a Parsons company, was competitively selected for the $500 million contract CHANTILLY, Va., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sealing Technologies (SealingTech), a Parsons Corporation company (NYSE: PSN), and leading defensive cyber operations solution provider, received an Intent to Award notification from the United States Cyber Command (USCYBERCOM) for a sole-source contract to begin production on the company’s Joint Cyber Hunt Kit solution. The three-year period of p...
Parsons to Present at the Barclays 43rd Annual Industrial Select Conference CHANTILLY, Va., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that Carey Smith, chair, president, and chief executive officer, and Matt Ofilos, chief financial officer, will participate in a fireside chat question and answer session at the Barclays 43rd Annual Industrial Select Conference on Wednesday, February 18, 2026, at approximately 3:35 p.m. Eastern Time. The presentation will be available live via webcast on the investor relations section of Parsons’ website (). A replay...
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combinatio...
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (internat...
Parsons Reports Fourth Quarter and Fiscal Year 2025 Q4 2025 Financial Highlights Q4 revenue of $1.6 billion decreased 8% year-over-year and 10% on an organic basisTotal revenue growth of 11% and 8% on an organic basis excluding confidential contractNet income of $56 million increased 3% year-over-year, a fourth quarter recordRecord adjusted EBITDA of $153 million increased 5%; adjusted EBITDA margin of 9.6%Cash flow from operations increased 32% to $168 millionBook-to-bill ratio of 0.9x and continued streak of TTM book-to-bill ratio of 1.0x or greater in every quarter since IPO Fiscal Ye...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.